Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study) User montaukwhaler, in the non small cell lung cancer subreddit, 26 Mar 2022